Close
Back to VIE Stock Lookup

(VIE) – Globe Newswire

Mar 1, 2021 04:01 PM Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
Mar 1, 2021 04:01 PM Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
Feb 25, 2021 08:30 AM Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
Feb 25, 2021 08:30 AM Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
Feb 23, 2021 08:00 AM INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, VIE, CLGX, CRHM; Shareholders Are Encouraged to Contact the Firm
Feb 22, 2021 07:00 AM Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
Feb 22, 2021 07:00 AM Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
Feb 1, 2021 02:05 PM VIELA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of VIE and Encourages Investors to Contact the Firm
Nov 10, 2020 04:15 PM Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
Nov 10, 2020 04:15 PM Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
Nov 5, 2020 04:01 PM Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
Nov 5, 2020 04:01 PM Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
Nov 2, 2020 07:00 AM Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
Nov 2, 2020 07:00 AM Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
Sep 3, 2020 04:01 PM Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
Sep 3, 2020 04:01 PM Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
Aug 12, 2020 04:15 PM Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
Aug 12, 2020 04:15 PM Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
Aug 5, 2020 07:00 AM Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
Aug 5, 2020 07:00 AM Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
Jun 11, 2020 05:45 PM Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Jun 11, 2020 05:45 PM Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
May 27, 2020 10:41 PM Viela Bio Announces Pricing of Public Offering of Common Stock
May 27, 2020 10:40 PM Viela Bio Announces Pricing of Public Offering of Common Stock
May 26, 2020 07:24 AM Viela Bio Announces Proposed Public Offering of Common Stock
May 26, 2020 07:23 AM Viela Bio Announces Proposed Public Offering of Common Stock
May 13, 2020 04:15 PM Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
May 13, 2020 04:15 PM Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
May 13, 2020 04:10 PM Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
May 13, 2020 04:10 PM Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
May 6, 2020 07:00 AM Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
May 6, 2020 07:00 AM Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
Apr 30, 2020 04:15 PM Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
Apr 30, 2020 04:15 PM Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
Mar 25, 2020 04:15 PM Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Mar 25, 2020 04:15 PM Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Mar 18, 2020 07:00 AM Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
Mar 18, 2020 07:00 AM Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
Dec 11, 2019 07:00 AM Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
Dec 11, 2019 07:00 AM Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
Nov 14, 2019 04:00 PM Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
Nov 14, 2019 04:00 PM Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
Oct 9, 2019 06:00 AM Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
Oct 7, 2019 04:05 PM Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Oct 7, 2019 04:05 PM Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Oct 2, 2019 09:54 PM Viela Bio Announces Pricing of Initial Public Offering

Back to VIE Stock Lookup